To address this, we systematically examined the clinical implications of 23 potentially functional polymorphisms in ten autophagy core genes (ATG2B, ATG3, ATG4C, ATG5, ATG7, ATG9B, ATG10, ATG12, ATG16L2 and BECN) in advanced lung adenocarcinoma who received gefitinib therapy. Here, ATG16L2 is linked to lung adenocarcinoma.